Inherited retirement accounts: What are your options?
Avenues for taking distributions vary according to the decedent’s age.
Related Articles
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
A primary concern was establishing trust in the connectivity to ensure no loss in visualization or connection.
Current Standards of Care and Shifting Strategies in NMIBC
Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions,…
CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC
The CHAI biomarker was shown to outperform EAU and AUA stratifications.
64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence
The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin.
Vignesh Packiam, MD, on choosing between options in NMIBC
“At the end of the day, it’s going to be unlikely that we’re going to use a single therapy for all of our patients,” says…
From prep to follow-up: Key considerations for administering onabotulinumtoxinA
Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.
OnabotA for OAB: Enhancing comfort and ensuring adherence
Karyn S. Eliber, MD,’s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
The approval is supported by findings from the phase 3 ENVISION trial.
Strategies to bridge gender disparities in AAS and citations in the oncology literature
One key approach is to increase the representation of women on editorial boards of journals and as reviewers.
Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.